By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK translational genomics firm Horizon Discovery said that it has joined a personalized medicine consortium created last year to apply functional genomics to develop drugs and identify biomarkers that may be predictive of drug responses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.